ArticleArthritis research & therapy2025
Roles of JAK-STAT signaling and granulocyte-macrophage colony-stimulating factor in the development of osteitis and bone microstructure changes in rheumatoid arthritis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LNGFR promoting osteogenic differentiation of ectomesenchyme stem cells via activation of GHR-JAK-STAT/IGF1 signaling pathway.Stem cell research & therapy · 2026Article
- CT imaging characteristics analysis of bone erosion in rheumatoid arthritis and bioinformatics study of inflammation-related gene rG4s.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundOsteitis on magnetic resonance imaging (MRI) and bone microstructure changes (BMC) on high-resolution peripheral quantitative computed tomography (CT) are the earliest signs of arthritis, preceding the development of bone erosion on X-ray in rheumatoid arthritis (RA). Recently, a Janus kinase (JAK) inhibitor, baricitinib, reportedly suppresses these early changes. This study aimed to elucidate the underlying molecular mechanism of osteitis and BMC using an animal model of RA and human samples.
methodsOsteitis and BMCs were assessed via MRI and micro-CT, respectively, in zymosan-treated SKG mice. Bone marrow (BM) cells were analysed via flow cytometry. JAK‒signal transducer and activator of transcription (STAT) cytokine expression was measured via performing quantitative PCR. Zymosan-treated SKG mice received baricitinib, anti-granulocyte‒macrophage colony-stimulating factor (GM-CSF) antibodies, or recombinant GM-CSF (r-GM-CSF). r-GM-CSF was also used in an in vitro osteoclast differentiation assay. Osteoclast differentiation was also investigated with human monocytes.
resultsOsteitis and BMCs occurred prior to arthritis in SKG mice. Granulocyte‒macrophage-lineage cells and osteoclast precursor cells (OCPs) expanded in the inflammatory BM. Receptor activator of nuclear factor kappa-B ligand-positive osteoclasts were observed at BMC sites. The expression of GM-CSF, a JAK‒STAT cytokine, was upregulated in osteitic BM. Both baricitinib and anti-GM-CSF antibodies suppressed osteitis and BMCs, whereas r-GM-CSF exacerbated these changes. In vitro addition of r-GM-CSF to osteoclast differentiation assay markedly increased the number and size of osteoclasts, especially when added in the late phase of osteoclast differentiation both in mice and humans.
conclusionsGM-CSF drives osteitis and BMCs by increasing granulocyte‒macrophage-lineage cells and OCPs and promoting osteoclast differentiation. Targeting GM-CSF is a potential therapeutic strategy to prevent early radiographic changes in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.